Rapamycin interacts synergistically with idarubicin to induce T-leukemia cell apoptosis in vitro and in a mesenchymal stem cell simulated drug-resistant microenvironment via Akt/mammalian target of rapamycin and extracellular signal-related kinase signaling pathways

Leukemia and Lymphoma

Volumn 55, Issue 3, 2014, Pages 668-676

  Wu, Kang Ni ^a   Zhao, Yan Min ^a   He, Ying ^a   Wang, Bin Sheng ^a   Du, Kai Li ^a   Fu, Shan ^a   Hu, Kai Min ^a   Zhang, Li Fei ^a   Liu, Li Zhen ^a   Hu, Yong Xian ^a   Wang, Ying Jia ^a   Huang, He ^a  

^a First Affiliated Hospital   (China)

Author keywords

Acute lymphoblastic leukemia; Idarubicin; Mesenchymal stem cell; Rapamycin; Synergistic effect

Indexed keywords

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; IDARUBICIN; LEUKEMIA, T-CELL; MESENCHYMAL STROMAL CELLS; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUMOR MICROENVIRONMENT;

EID: 84894439079     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.811579     Document Type: Article

References (36)

1. Palomero T, Dominguez M, Ferrando AA. The role of the PTEN/AKT pathway in NOTCH1-induced leukemia. Cell Cycle 2008; 7:965-970.
2. Gutierrez A, Look AT. NOTCH and PI3K-AKT pathways intertwined. Cancer Cell 2007;12:411-413.
3. Zhang C, Ryu nc Chen TZ, et al. Synergistic activity of rapamycin and dexamethasone in vitro and in vivo in acute lymphoblastic leukemia via cell-cycle arrest and apoptosis. Leuk Res 2012;36:342-349.
4. Zhao YM, Zhou Q, Xu Y, et al. Antiproliferative effect of rapamycin on human T-cell leukemia cell line Jurkat by cell cycle arrest and telomerase inhibition. Acta Pharmacol Sin 2008;29:481-488.
5. Batista A, Barata JT, Raderschall E, et al. Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors. Exp Hematol 2011;39:457-472.e3.
6. Yu C, Mao X, Li WX. Inhibition of the P131( pathway sensitizes fludarabine-induced apoptosis in human leukemic cells through an inactivation of MAPK-dependent pathway. Biochem Biophys Res Commun 2005;331:391-397.
7. Steelman LS, Franklin RA, Abrams SL, et al. Roles of the Ras/ Raf/MEIC/ERIC pathway in leukemia therapy. Leukemia 2011;25: 1080-1094.
8. Hahn M, Li W, Yu C, et al. Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEI(/ERK, Akt, and JNI( signal transduction pathways. Mol Cancer Ther 2005;4:457-470.
9. Romano MF, Avellino R, Petrella A, et al. Rapamycin inhibits doxorubicin-induced NF- kappaB/Rel nuclear activity and enhances the apoptosis of melanoma cells. Eur J Cancer 2004;40:2829-2836.
10. Laurent G, Jaffrezou JP. Signaling pathways activated by daunorubicin. Blood 2001;98:913-924.
11. Yu HG, Ai YW, Yu LL, et al. Phosphoinositide 3-kinaselAkt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. Tnt J Cancer 2008; 122:433-443.
12. McCubrey JA, Abrams SL, Ligresti G, et al. Involvement of p53 and Raf/MEIC/ERIC pathways in hematopoietic drug resistance. Leukemia 2008;22:2080-2090.
13. Greenberg JM, Gonzalez-Sarmiento R, Arthur DC, et al. Immunophenotypic and cytogenetic analysis of Molt-3 and Molt-4: human T-lymphoid cell lines with rearrangement of chromosome 7. Blood 1988;72:1755-1760.
14. Schneider U, Schwenk HU, Bornkamm G. Characterization of EBV-genome negative "null" and "T" cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non- Hodgkin lymphoma. Tnt J Cancer 1977;19:621-626.
15. Foley GE, Lazarus H, Farber 5, et al. Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia. Cancer 1965;18:522-529.
16. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
17. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621-681.
18. Nwabo Kamdje AH, Mosna F, Bifari F, et al. Notch-3 and Notch-4 signaling rescue from apoptosis human B-ALL cells in contact with human bone marrow-derived mesenchymal stromal cells. Blood 2011;118:380-389.
19. Thomas 5, Quinn BA, Das 5K, et al. Targeting the Bcl-2 family for cancer therapy. Expert Opin Ther Targets 2013;17:61-75.
20. O'Gorman DM, McI(enna SL, McGahon AJ, et al. Sensitisation of HL6O human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of P13-kinase survival signals. Leukemia 2000;14:602-611.
21. Martelli AM, Evangelisti C, Chappell W, et al. Targeting the translational apparatus to improve leukemia therapy: roles of the P131(1 PTENIAktImTOR pathway. Leukemia 201 1;25:1064-1079.
22. Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci 2011; 36:320-328.
23. Dc Luca A, Maiello MR, D'Alessio A, et al. The RAS/RAF/MEI(/ ERIC and the P131(IAI(T signalling pathways: role in cancer p athogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 2012;16(Suppl. 2):517-527.
24. Ivanyi P, Morgan M, Piao W, et al. Pre T-cell receptor alpha pTalpha) expression patterns and functional analysis in human T- cell lymphoblastic leukemia. Cell Oncol 2010;32:101-108.
25. Zhao YM, Wu KN, Wang YT, et al. [Synergistic cytotoxic effects of rapamycin and idarubicin on human acute T-cell lymphoblastic leukemia Jurkat cells]. Zhejiang Da Xue Xue Bao Yi Xue Ban 2011;40: 482-488.
26. Weisberg E, Azab AK, Manley PW, et al. Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrowmicroenvironment and sensitizes them to nilotinib. Leukemia 2012;26:985-990.
27. Tesfai Y, Ford J, Carter KW, et al. Interactions between acute lymphoblastic leukemia and bone marrow stromal cells influence response to therapy. LeukRes 2012;36:299-306.
28. Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003;425:841-846.
29. Nwabo Kamdje AH, Krampera M. Notch signaling in acute lymphoblastic leukemia: any role for stromal microenvironment? Blood 2011;118:6506-6514.
30. Iumagai M, Manabe A, Coustan-Smith E, et al. Use of stromasupported cultures of leukemic cells to assess antileukemic drugs. II. Potent cytotoxicity of2-chloro-deoxyadenosine in acute lymphoblastic leukemia. Leukemia 1994;8:1116-1123.
31. Umiel T, Friedman 5, Zaizov R, et al. Long-term culture of infant leukemia cells: dependence upon stromal cells from the bone marrow and bilineage differentiation. Leuk Res 1986;10:1007-1013.
32. Gluck U, Zipori D, Wetzler M, et al. Long-term proliferation of human leukemia cells induced by mouse stroma. Exp Hematol 1989; 17:398-404.
33. Ayala F, Dewar R, Kieran M, et al. Contribution of bone microenvironment to leukemogenesis and leukemia progression. Leukemia 2009;23:2233-2241.
34. Iconopleva M, I(onoplev 5, Hu W, et al. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia 2002;16:1713-1724.
35. Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromalderived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia 2003;17:1175-1182.
36. Fortney JE, Zhao W, Wenger SL, et al. Bone marrow stromal cells regulate caspase 3 activity in leukemic cells during chemotherapy. Leuk Res 2001;25:901-907.